SecBot SecBot
SECBOTREPLAY Home › Report › FATE

FATE · FATE THERAPEUTICS INC filed a definitive proxy statement for its 2026…

FATE THERAPEUTICS INC · DEFA14A filed Apr 24, 2026 at 16:08 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 24, 2026 at 16:08 ET

FATE THERAPEUTICS INC filed a definitive proxy statement for its 2026 annual shareholder meeting, proposing the election of three Class I directors, ratification of auditors, advisory approval of executive compensation, and an increase in shares available under its stock option plan.

  • Annual shareholder meeting scheduled for June 12, 2026
  • Proposing election of three Class I directors: Robert S. Epstein, Karin Jooss, and Laura J. Hamill
  • Proposing to increase shares available under the 2022 Stock Option and Incentive Plan
  • Proposing ratification of Ernst & Young LLP as independent auditors

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access